We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Oct 2023 to Apr 2024
By Ben Glickman
Merck's candidate to treat chronic cough didn't show substantial evidence of effectiveness, according to the Food and Drug Administration.
The Rahway, N.J.-based pharmaceutical company said Wednesday it received a complete response letter from the FDA regarding its new drug application for gefapixant, a potential treatment for refractory chronic cough or unexplained chronic cough in adults.
The company said the letter wasn't related to the safety of the treatment, and it was reviewing FDA feedback to determine the next steps.
RCC is a persistent cough that continues despite treatment of underlying conditions, while UCC is a persistent cough without an identified underlying cause.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:12 ET (22:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
